Published on February 3, 2010 at 3:54 AM
NanoBio
Corporation announced today that a sixth U.S. patent covering its
novel nanoemulsion technology has been awarded. The patent encompasses
composition of matter claims for the company’s lead anti-infective and
vaccine product candidates.
“We are very pleased with this patent award in that the new claims
circumscribe all of NanoBio’s anti-infective and dermatological
products, as well as our intranasal and intramuscular vaccine
adjuvants”
“We are very pleased with this patent award in that the new claims
circumscribe all of NanoBio’s anti-infective and dermatological
products, as well as our intranasal and intramuscular vaccine
adjuvants,” said James R. Baker, Jr., MD, NanoBio’s CEO and founder.
“The timing of this allowance coincides nicely with several very
important development milestones at NanoBio.”
In December 2009, NanoBio and GlaxoSmithKline plc (GSK) announced an
exclusive licensing agreement in the United States and Canada for the
over-the-counter use of NB-001, NanoBio’s lead product for the treatment
of herpes labialis (cold sores). NanoBio is currently preparing to study
the efficacy and safety of 0.3% NB-001 in two Phase 3 trials.
In addition, NanoBio’s lead vaccine candidate, NB-1008, a seasonal
influenza vaccine administered via a nasal dropper, has shown very
promising results in a recently completed Phase 1 clinical study. The
company is currently in partnership discussions with several parties
regarding NB-1008.
The development of the nanoemulsion platform began in the 1990s at the
University of Michigan, and has since been supported by over $110
million in grants, investments and partnership funding. The newly issued
patent (U.S. #7,655,252) is licensed from the University of Michigan to
NanoBio Corp. on an exclusive, worldwide basis. With this new patent,
NanoBio now holds six U.S. patents and has filed over 30 additional
applications.
SOURCE NanoBio Corp.